ERBB2 and breast carcinoma: In 2016, Meghan et al. found that RICTOR was enriched in HER2-amplified samples and proved that RICTOR-mediated Akt phosphorylation (s473), instead of mTORC1-mediated phosphorylation, could maintain the survival of HER2-amplified breast cancer cells.